AMY ALLEN: Open Payments
NPI 1962006304 · FRISCO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,707 in 217 payments from 20 companies in 2025. Trend: 2023 $3,063 · 2024 $3,315 · 2025 $3,707
Food & beverage: $3,699Education: $8
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $481 |
| Neurocrine BioSciences, Inc. | 19 | $414 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $384 |
| Janssen Pharmaceuticals, Inc | 32 | $337 |
| Otsuka America Pharmaceutical, Inc. | 18 | $318 |
| E.R. Squibb & Sons, L.L.C. | 16 | $271 |
| Corium, LLC | 11 | $238 |
| Teva Pharmaceuticals USA, Inc. | 12 | $216 |
| Vanda Pharmaceuticals Inc. | 13 | $198 |
| Axsome Therapeutics, Inc. | 11 | $157 |
Products named: VRAYLAR, INGREZZA, CAPLYTA, REXULTI, COBENFY, Azstarys, FANAPT, SPRAVATO.
Industry payments across TX — which companies pay providers there.
